Chengdu biological pharmaceutical industry introduced to promote the development of special policy

Up 11.8 million yuan to support new drug research and development

The 2016-08-03 05:15:34

Source: sichuan daily (chengdu)

Report from our correspondent (reporter Jiang Junfang) on August 2, the reporter learned from the information office of chengdu city government that "about accelerating the development of biological medicine industry of chengdu special policy" has been printed in a formal, this is the first time in chengdu special policy introduced biological medicine field.

"Chengdu 2025 planning" chengdu biological pharmaceutical industry as one of five speed up the development of strategic emerging industries. The object of policy support for our country present stage "much starker choices-and graver consequences-in planning" key support for research and development direction, general products not included in the support scope. In addition, introduced the special policy has strong pertinence, based on the analysis of biological medicine industry "3 tall one long" (high input, high risk, high return, long cycle) characteristics, makes every effort to achieve precise support.

Chengdu by committee, deputy director of the cold ZhiYong introduction letter, an innovative drug development cycle to be 10 to 15 years, the research and development cost is 1 billion yuan, medical equipment research and development cycle and cost on the basis of different product differences, high-end medical equipment development cycle for 8 to 10 years, fees can amount to tens of millions of yuan. Policy for research and development of this special link, the key period, strive for new drugs, medical apparatus and instruments according to the research and development progress in stages, boost the development of new products. A class 1 new drug, obtains the highest may obtain 800000 yuan to support clinical to accept order, in clinical stage 1, 2, 3 phase can obtain 1 million yuan, 2 million yuan and 3 million yuan respectively, obtain approval documents registered the highest support may obtain 5 million yuan, a total of 11.8 million yuan can obtain the highest support.

To encourage the city's drug firms products into the catalog of national essential drugs and the national basic medical insurance and industrial injury insurance drug catalogue, new into the catalog of national essential drug policy for the exclusive varieties or exclusive dosage forms, giving each product 500000 yuan one-time cash reward; For new entrants to the national basic medical insurance and industrial injury insurance drug catalogue of exclusive varieties, each species 200000 yuan one-time cash incentives.

Focus on the development of the local at the same time, the policy has also encouraged the biological medicine enterprise to obtain the FDA certification, the eu cGMP certification, certification of the world health organization and other international market access certification, expand overseas markets, to obtain overseas market access enterprise give one-off reward 1 million yuan; Encourage the biological medicine companies provide biotechnology offshore services for overseas, speed is in line with international standards, to provide foreign institutions with the city biotechnology offshore services of biological pharmaceutical companies, according to last year's technology offshore service 10% of the total amount of income shall be rewarded.